logo UCSF Benioff Children's Hospital Oakland
Hematology/Oncology Department
Research Studies Open for Enrollment
Date: 01/26/2021

Oncology:

Title ID/Protocol NCT/Phase Sponsor P.I. Contact
NEURO-ONCOLOGY
Oncology, Neuro-Onc
Phase 2 Study of Reduced Therapy for Newly Diagnosed Average-Risk WNT-Driven Medulloblastoma PatientsACNS1422 NCT02724579
Phase 2
COGCarla Golden, MDSheila Contapay-Tabilin, BSN, RN (510-428-3885 x 2611)<
Oncology, Neuro-Onc, Solid Tumors
Clinical/Molecular Risk-Tailored Intensive, Compressed Induction Chemotherapy Followed by Consolidation Randomization To Single-Cycle or 3 Tandem Cycles of Marrow-Ablative Chemo with Hematopoietic Progenitor Cell RescueHead-Start-4 NCT02875314
Phase 4
Next Consortium, Nationwide Children'sCaroline Hastings, MDEffie Bourgin
ONCOLOGY
Pediatric Tissue Bank at the Children's Hospital & Research Center OaklandONC Tissue Bank N/A
Jon Rowland, MD
The Effectiveness of Lactobacillus plantarum (LBP, IND# 17339) in Preventing Acute Graft-versus-Host Disease (GvHD) in Children undergoing Alternative Progenitor Cell TransplantationACCL1633 NCT03057054
Phase 3
COGCarla Golden, MDSheila Contapay-Tabilin, BSN, RN (510-428-3885 x 2611)<
Oncology
Key Adverse Events after Childhood CancerALTE03N1 NCT00082745
N/A
COGCarla Golden, MDSheila Contapay-Tabilin, BSN, RN (510-428-3885 x 2611)<
Neuropsychological, Social, Emotional and Behavioral Outcomes in Children with CancerALTE07C1 NCT00772200
N/A
COGCarla Golden, MDSheila Contapay-Tabilin, BSN, RN (510-428-3885 x 2611)<
Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research ProgramDCP-001 N/A
N/A
NCORPCarla Golden, MDSheila Contapay-Tabilin, BSN, RN (510-428-3885 x 2611)<
Oncology, Leukemia
An Open-Label, Multicenter Study of RC-P in Patients with Acute Lymphoblastic Leukemia (ALL)/Lymphoblastic Lymphoma (LBL) Following Hypersensitivity to E. coli-derived AsparaginasesAALL1931 NCT04145531
Phase 2/3
COG/GJazz PharmaceuticalsCarla Golden, MDSheila Contapay-Tabilin, BSN, RN (510-428-3885 x 2611)<
International Phase 3 Trial in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Ph+ ALL Testing Imatinib in Combination with Two Different Cytotoxic Chemotherapy BackbonesAALL1631 NCT03007147
Phase 3
COGCarla Golden, MDSheila Contapay-Tabilin, BSN, RN (510-428-3885 x 2611)<
Phase 3 Trail of IND# 117467 (Blinatumomab) in Combination with Chemotherapy in Patients with Newly Diagnosed Stanrd Risk/Down Syndrome B-ALL and Localized B-LlyAALL1731 NCT03914625
Phase 3
COGCarla Golden, MDSheila Contapay-Tabilin, BSN, RN (510-428-3885 x 2611)<
Risk-stratified Therapy for Acute Myeloid Leukemia in Down SyndromeAAML1531 NCT02521493
Phase 3
COGCarla Golden, MDSheila Contapay-Tabilin, BSN, RN (510-428-3885 x 2611)<
Oncology, Leukemia, Lymphoma, Solid Tumors
A Randomized Web-based Physical Activity Intervention among Children and Adolescents with CancerALTE1631 NCT03223753
Phase 3
COGCarla Golden, MDSheila Contapay-Tabilin, BSN, RN (510-428-3885 x 2611)<
Oncology, Neuro-Onc
A Phase 2 Study of Veliparib (ABT-888, IND # 139199) and Local Irradiation, Followed by Maintenance Veliparib and Temozolomide, in Patients with Newly Diagnosed High-Grade Glioma (HGG) without H3 K27M or BRAFV600 MutationsACNS1721 NCT03581292
Phase 2
COGCarla Golden, MDSheila Contapay-Tabilin, BSN, RN (510-428-3885 x 2611)<
Oncology, Neuro-Onc, Leukemia, Lymphoma, Solid Tumors
Establishing Continuous Cell Lines and xenografts from Pediatric Cancers for Biological and Pre-Clinical Therapeutic StudiesABTR04B1 NCT00898755
COGCarla Golden, MDSheila Contapay-Tabilin, BSN, RN (510-428-3885 x 2611)<
Project:EveryChild A Registry, Eligibility Screening, Biology and Outcome StudyAPEC14B1 NCT02402244
N/A
COGCarla Golden, MDSheila Contapay-Tabilin, BSN, RN (510-428-3885 x 2611)<
Oncology, Oncology: Early Phase, Lymphoma, Solid Tumors
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Screening ProtocolAPEC1621SC NCT03155620
Phase 2
COGCarla Golden, MDSheila Contapay-Tabilin, BSN, RN (510-428-3885 x 2611)<
Oncology, Oncology: Early Phase, Solid Tumors
Master NCI COG Pediatric MATCH (Molecular Analysis for Therapy Choice)APEC1621 N/A
Phase 2
COGCarla Golden, MDSheila Contapay-Tabilin, BSN, RN (510-428-3885 x 2611)<
Oncology, Solid Tumors
Effects of Modern Chemotherapy Regimens on Spermatogenesis and Steroidogenesis in Adolescent and Young Adult Osteosarcoma SurvivorsALTE16C1 NCT03206450
N/A
COGCarla Golden, MDSheila Contapay-Tabilin, BSN, RN (510-428-3885 x 2611)<
LEAHRN (Late Effects After High-Risk Neuroblastoma) StudyALTE15N2 NCT03057626
N/A
COGCarla Golden, MDSheila Contapay-Tabilin, BSN, RN (510-428-3885 x 2611)<
Neuroblastoma Classification Biology StudiesANBL00B1 NCT00904241
COGCarla Golden, MDSheila Contapay-Tabilin, BSN, RN (510-428-3885 x 2611)<
Pediatric Hepatic Malignancy International Therapeutic Trial (PHITT)AHEP1531 NCT03533582
Phase 3
COGCarla Golden, MDSheila Contapay-Tabilin, BSN, RN (510-428-3885 x 2611)<
Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients with Germ Cell TumorsAGCT1531 NCT03067181
Phase 3
COGCarla Golden, MDSheila Contapay-Tabilin, BSN, RN (510-428-3885 x 2611)<
Randomized Phase 3 Study of Vincristine, Dactinomycin, Cyclophosphamide (VAC) Alt. w. Vincristine/Irinotecan (VI) Vs VAC/VI Plus Temsirolimus in Patients with Intermediate Risk RhabdomyosarcomaARST1431 NCT02567435
Phase 3
COGCarla Golden, MDSheila Contapay-Tabilin, BSN, RN (510-428-3885 x 2611)<
Renal Tumors Classification, Biology, and Banking StudyAREN03B2 NCT00945009
Phase 3
COGCarla Golden, MDSheila Contapay-Tabilin, BSN, RN (510-428-3885 x 2611)<
Utilizing Response- and Biology-Based Risk Factors to Guide Therapy in Patients with Non-High-Risk NeuroblastomaANBL1232 NCT02176967
Phase 3
COGCarla Golden, MDSheila Contapay-Tabilin, BSN, RN (510-428-3885 x 2611)<
ONCOLOGY: EARLY PHASE
A Study Using Molecular Guided Therapy with Induction Chemotherapy followed by a Randomized Controlled Trial of standard Immunotherapy with or w/o DFMO followed by DFMO maintenance for Newly Diagnosed High-Risk NeuroblastomaNMTRC012 NCT02559778
Phase 2
Beat Childhood Cancer (BCC)Anu Agrawal, MDJennifer Michlitsch, MD
Leukemia, Lymphoma
Pilot Study of Mitoxantrone in combination with Clofarabine in Children, Adolescents and Young Adults with Refractory/Relapsed Acute Leukemia or High Grade Non-Hodgkin LymphomaMITCL NCT01842672
Phase 1/2a
New York Medical CollegeJennifer Michlitsch, MDJennifer Michlitsch, MD
Lymphoma, Solid Tumors
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 subprotocol of tazemetostat for patients with tumors harboring alterations in EZH2 or members of the SWI/SNF complexAPEC1621C NCT03213665
Phase 2
COGCarla Golden, MDSheila Contapay-Tabilin, BSN, RN (510-428-3885 x 2611)<
Oncology, Neuro-Onc, Oncology: Early Phase, Lymphoma, Solid Tumors
NCI-COG PEDIATRIC MATCH (MOLECULAR ANALYSIS FOR THERAPY CHOICE) - PHASE 2 SUBPROTOCOL OF AG-120 (IVOSIDENIB) IN PATIENTS WITH TUMORS HARBORING IDH1 MUTATIONSAPEC1621K NCT04195555
Phase 2
COGCarla Golden, MDSheila Contapay-Tabilin, BSN, RN (510-428-3885 x 2611)<
Oncology, Oncology: Early Phase
Open-Label, Multicenter, Phase 2 Study Evaluating Efficacy and Safety of Daratumumab in Ped and Young Adults >=1 and =<30 Years with Relapsed/Refractory Precursor B-cell or T-cell ALLDaratumumab Anu Agrawal, MD (510-428-3885 x3539)
Oncology, Oncology: Early Phase, Lymphoma, Solid Tumors
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of BVD-523FB (ulixertinib) in Patients with Tumors Harboring Activating MAPK Pathway MutationsAPEC1621J NCT03698994
Phase 2
COGCarla Golden, MDSheila Contapay-Tabilin, BSN, RN (510-428-3885 x 2611)<
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 subprotocol of JNJ-42756493 (Erdafitinib) in patients with tumors harboring FGFR1/2/3/4 alterationsAPEC1621B NCT03210714
Phase 2
COGCarla Golden, MDSheila Contapay-Tabilin, BSN, RN (510-428-3885 x 2611)<
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 subprotocol of LOXO-101 (larotrectinib) in patients with tumors harboring actionable NTRK fusionsAPEC1621A NCT03213704
Phase 2
COGCarla Golden, MDSheila Contapay-Tabilin, BSN, RN (510-428-3885 x 2611)<
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 subprotocol of LY3023414 in Solid TumorsAPEC1621D NCT03155620
Phase 2
COGCarla Golden, MDSheila Contapay-Tabilin, BSN, RN (510-428-3885 x 2611)<
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 subprotocol of Palbociclib in Patients with Tumors Harboring Activating Alterations in Cell Cycle GenesAPEC1621I NCT03526250
Phase 2
COGCarla Golden, MDSheila Contapay-Tabilin, BSN, RN (510-428-3885 x 2611)<
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 subprotocol of olaparib in patients with tumors harboring defects in DNA damage repair genesAPEC1621H NCT03233204
Phase 2
COGCarla Golden, MDSheila Contapay-Tabilin, BSN, RN (510-428-3885 x 2611)<
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- Phase 2 subprotocol of Vemurafenib in patients with tumors harboring actionable BRAF V600 mutationsAPEC1621G NCT03220035
Phase 2
COGCarla Golden, MDSheila Contapay-Tabilin, BSN, RN (510-428-3885 x 2611)<
Solid Tumors
Neuroblastoma Maintenance Therapy Trial Using DifluoromethylornithineNMTRC-014 NCT02679144
Phase 2
Beat Childhood Cancer (BCC)Anu Agrawal, MDAnu Agrawal, MD (510-428-3885 x3539)
Two-Part Study of TB-403 in Pediatric Subjects with Relapsed or Refractory Medulloblastoma, Neuroblastoma, Ewing Sarcoma or Alveolar RhabdomyosarcomaTB-403 NCT02748135
Phase 1/2a
Beat Childhood Cancer (BCC) and Oncurious NVJennifer Michlitsch, MDJennifer Michlitsch, MD (510-428-3885 x3264)
STEM CELL TRANSP AND CELLULAR THERAPY
Oncology
Role of KIR-favorably Mismatched Haploidentical Transplantation and KIR-polymorphisms in Determining Outcomes of Children with ALL/AML/MDS Undergoing Allogeneic Hematopoietic Cell TransplantationONC1401 NCT02646839
Phase 1/2
Pediatric Blood and Marrow Transplatn ConsortiumNahal Rose Lalefar, MDMarci Moriarty, RN (510-428-3385 x5396)
Oncology: Early Phase, Leukemia
Pediatric and Young Adult Leukemia Adoptive Therapy. A Phase 1/2 Feasibility and Safety Study of CD19-CAR T Cell Immunotherapy for CD19+ LeukemiaPLAT-02 NCT02028455
Phase 1/2
Seattle Children's HospitalAnu Agrawal, MDMarci Moriarty, RN (510-428-3385 x5396)

UCSF Benioff Children's Hospital Oakland • 747 52nd Street, Oakland, California 94609 • Phone: (510) 428-3000